

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

EXPRESS MAIL LABEL No  
EJ 339 571 850 US

DATE  
April 18, 2000

ATTORNEY'S DOCKET NO  
A33131-PCT-USA 67858.0101

US APPLICATION NO  
To be assigned

09/529759

INTERNATIONAL APPLICATION NO  
PCT/FR98/02244

INTERNATIONAL FILING DATE  
October 20, 1998

PRIORITY DATE CLAIMED  
October 20, 1997

TITLE OF INVENTION

Documentation Means for Repertoires of NKR Immunoreceptors and/or Acitvatory or Non-Inhibitory Immunoreceptor Counterparts of NKR Immunoreceptors

APPLICANT(S) FOR DO/EO/US

Insert


Applicant herewith submits to the United States Designated /Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

422 Rec'd PCT/PTO 1 8 APR 2000

INTERNATIONAL APPLICATION NO <b>09/529759</b>		INTERNATIONAL FILING DATE October 20, 1998		PRIORITY DATE CLAIMED October 20, 1997	
17. <input type="checkbox"/> The following fees are submitted:					
<b>Basic National Fee (37 CFR 1.492(a)(1)-(5):</b>  Neither international preliminary examination fee (37 CFR 1.482)  Nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO (1.492(a)(3)) ..... \$970.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO (1.492(a)(5)) ..... \$840.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO (1.492(a)(2)) ..... \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) (1.492(a)(1)) ..... \$670.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$ 96.00				<b>CALCULATIONS</b> <small>PTO USE ONLY</small>	
<b>ENTER APPROPRIATE BASIC FEE AMOUNT</b>				= \$ 840.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).				\$	
<b>Claims</b>	<b>Number Filed</b>	<b>Number Extra</b>	<b>Rate</b>	<b>\$</b>	
Total Claims	23-20=	3	X \$ 18.00	\$ 54.00	
Independent Claims	5-3=	2	X \$ 78.00	\$ 156.00	
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$ 260.00	
<b>TOTAL OF ABOVE CALCULATIONS</b>				= \$ 1310.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$	
<b>SUBTOTAL</b>				= \$ 1310.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+ \$	
<b>TOTAL NATIONAL FEE</b>				= \$ 1310.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+ \$ 40.00	
<b>TOTAL FEES ENCLOSED</b>				= \$ 1350.00	
				<b>Amt. refunded</b>	\$
				<b>charged</b>	\$ 1350.00
a. <input checked="" type="checkbox"/> A check in the amount of \$ 1350.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge our Deposit Account No. <u>02-4377</u> in amount of \$_____ to cover the above fees. A copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-4377</u> . A copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
<b>SEND ALL CORRESPONDENCE TO:</b>					
BAKER BOTTS L.L.P. 30 Rockefeller Plaza New York, New York 10112-4498			 Carmella L. Stephens Registration No. 41,328		
			John D. Murnane Registration No. 29,836		

2/pars

09/529759

422 Rec'd PCT/PTO 1 8 APR 2000

WO 99/20794

PCT/FR98/02244

Means of documenting repertoires of NKR immunoreceptors  
and/or of activatory or non-inhibitory immunoreceptor  
counterparts of NKR immunoreceptors

5           The present invention relates to means which  
make it possible to document the repertoires, in an  
individual or an animal, of NKR (*Natural Killer*  
Receptor) immunoreceptors of the immunoglobulin type or  
of the lectin type, and of activatory, or at the very  
10 least non-inhibitory, immunoreceptor counterparts of  
NKR immunoreceptors. It also relates to their  
biological applications.

          The immune functions in humans or animals are  
defined by several categories of highly diversified  
15 molecules, such as in particular the ABO blood group  
system, the family of MHC (Major Histocompatibility  
Complex, called, in humans, HLA - *Human Leukocyte*  
Antigen - system) molecules, the family of receptors  
for the T lymphocyte antigen (TCR) and B lymphocyte  
20 antigen (BCR). All the molecules which an adult  
individual expresses, or is capable of expressing, for  
each of these different families constitute, with the  
exception of identical twins, an evolutive repertoire  
which is specific to them and which is involved in self  
25 or non-self recognition.

          Other main repertoires have been more recently  
identified. They are the immunoglobulin-type NKR  
receptor repertoire and the lectin-type NKR receptor  
repertoire. The immunoglobulin-type NKR receptors  
30 comprise the KIR receptors (*Killer cell Inhibitory*  
Receptors) such as in particular the p58.1, p58.2,  
p70.INH and p140.INH receptors. The lectin-type NKR  
receptors comprise the inhibitory NKG2 receptors such  
as in particular the NKG2A and NKG2B receptors. All  
35 these NKR receptors have an inhibitory function.  
Receptors which are highly homologous to them, in  
particular at the extracytoplasmic level, however  
fulfil activatory, or at the very least non-inhibitory,

functions: they are the KAR receptors (Killer cell Activatory Receptors) which are homologous to the KIR receptors, and NKG2C, NKG2D, NKG2E and NKG2F receptors which are homologous to the NKG2A and NKG2B receptors.

- 5 The activatory, or at the very least non-inhibitory, receptor counterparts of the inhibitory NKR receptors are hereinafter designated, for the sake of convenience, NKR counterparts.

- 10 The NKR receptors and the NKR receptor counterparts are naturally expressed by the NK cells and by subpopulations of T cells. Several of these receptors may be expressed by the same cell. All these receptors, whether they are inhibitory (i.e. NKR) or activatory or non-inhibitory (i.e. NKR counterparts),  
15 have in common the fact that they have as ligand molecules which are not antigen-derived: the ligands for the NKR receptors and for the NKR receptor counterparts are MHC class I molecules.

- 20 The recognition of its ligand by an NKR receptor triggers the transduction, to the cell, of a message intended to inhibit its activity, e.g. reduction or termination of cytolysis, of secretion of cytokines, whereas the recognition of its ligand by an NKR receptor counterpart induces therein an activatory,  
25 or at the very least non-inhibitory, message. The result of the NKR receptors and NKR receptor counterparts thus activated by their ligands is a signal, which is negative or positive overall, for activation of the NK and/or T cells expressing them.

- 30 The NKR receptors and their counterparts thus participate in the positive or negative control of the allogenic reactions of a given immune system with respect to what it then considers as non-self for example, cancer cells or infected cells, or  
35 alternatively allo- or xeno-genic graft or transplant cells.

The NKR receptors and their counterparts indeed participate in the reactions between host and graft during a grafting (or transplantation) of cells, tissue

or organ which exhibit(s) a degree of antigenic incompatibility with the host. The involvement of NKR receptors and their counterparts in the tolerance towards incompatible grafts, and in the selective  
5 effect of lysis of malignant cells sometimes observed after a bone marrow graft, or GVL (*Graft Versus Leukemia*) effect, has indeed been demonstrated *in vivo* (cf. Cambiaggi et al. 1997, Proc. Natl. Acad. Sci. USA, vol. 94, p. 8088-8092; Albi et al. 1996, Blood, vol.  
10 87, No. 9, p. 3993-4000).

However, the means which can currently be used in a medical context do not make it possible to document all the repertoires of a patient, of an organ, of a tissue or of cells.

15 Accordingly, only the compatibility of the HLA-A, HLA-B and HLA-DR molecules of the donor and of the recipient is currently checked prior to an allo- or xeno-genic graft or transplant. These compatibility criteria do not however appear to be satisfactory.  
20 Immunosuppressive treatments (for example based on cyclosporin) should supplement these graft or transplant procedures so as to inhibit the patient's immune system. Such treatments have high risks for the patient who is then likely to develop opportunistic  
25 infections. These immunosuppressive treatments must furthermore be maintained at a certain level for several years, and the patient then has to withstand the damaging effects of the medicaments. Finally, the success of such graft or transplant procedures remains  
30 uncertain. Indeed, graft rejections on the part of the recipient, or alternatively, in the case of grafts comprising immunocompetent cells, graft-versus-host reactions (GVH effect) are nevertheless observed. Such rejection or GVH reactions generally lead to very  
35 severe lesions; currently, they cannot however be completely avoided, and therefore prevented.

Unexpected beneficial effects of allogenic grafts have, moreover, sometimes been observed: allogenic grafts of bone marrow in aplastic leukaemia

patients have sometimes led to a therapeutic antitumour effect through lysis of the malignant cells of the recipient and preservation of their healthy cells. This selective therapeutic effect, in which the NK and T cells are involved, is designated GVL (*Graft Versus Leukemia*). Potentially, a grafting (or a transplantation) of haematopoietic tissue in general, and of bone marrow in particular, can lead to a therapeutic effect in the context of haematological malignancies such as a leukaemia, through selective lysis of those cells from the recipient which no longer have the histocompatibility antigens presented by healthy cells. The means currently available to the medical setting do not make it possible, however, to predict if the organ or the tissue considered will exert a selective GVL effect for the recipient considered. Although known, the selective GVL effect cannot therefore be currently exploited in the context of an anticancer therapy.

The means currently developed in the context of experimental research studies in order to document the different repertoires of human or animal cells in fact do not make it possible to precisely document the repertoire of NKR receptors and of NKR receptor counterparts: the precise identity of each NKR receptor or NKR counterpart cannot be determined. Because of the strong homology, in particular at the extracytoplasmic level, between an NKR receptor and an NKR receptor counterpart (e.g. up to 96% homology between KIR and KAR), the use of antibodies indeed often do not make it possible to discriminate between NKRs which are inhibitory and their counterparts with activatory, or at the very least non-inhibitory, functions. The oligonucleotide primers which are currently available, for their part, do not allow the use of a polymerase chain reaction capable of discriminating between, for example, an NKR p58.1 and an NKR p58.2, or between an NKR p70.INH and an NKR p140.INH. Finally, to accurately document the repertoire of NKR immunoreceptors and of

their counterparts, use must currently be made, after a step of purifying the desired receptors (e.g. by FACScan), of a nucleotide sequencing step. The documenting of the NKR/NKR counterpart repertoire cannot therefore be currently performed routinely in a medical-type context. The level of stimulation and inhibition of the programmes of activation of the NK and T cells, and therefore the potential of an individual to be resistant to the development of microbial or parasitic infections, of autoimmune diseases, or alternatively of malignant cells, cannot therefore be measured. The result of this lack of suitable means for documenting NKR/NKR counterpart repertoires is also that the selective GVL-type effects cannot be used in therapy, and that the GVH or rejection reactions during allo- or xeno-genic grafts or transplants cannot be completely avoided.

The present invention therefore provides means which make it possible to document, for a given biological sample, the repertoires of NKR immunoreceptors and of activatory or at the very least non-inhibitory immunoreceptor counterparts of NKR receptors. These means make it possible in particular to easily distinguish between an NKR receptor and its activatory or non-inhibitory counterpart, as well as to distinguish between various NKR receptors, or between various NKR counterparts. It also relates to the biological, and in particular medical and veterinary, applications of these means. One of the essential aspects according to the invention consists in considering all the NKR immunoreceptors and NKR counterparts as a repertoire, that is to say as a coherent set, forming a unit with respect to a type of activity, in this case, in a particularly advantageous manner, the control of lymphocyte activation in humans or animals from which the said biological sample is derived (negative control for the NKR receptor repertoire, positive control for the NKR counterpart receptor). The invention provides, for the first time,

means which make it possible to document, routinely in a medical or veterinary context, NKR and/or NKR counterpart repertoires, so as to be able to rapidly and effectively analyse physiological and pathological situations linked to these repertoires.

The means according to the invention have in particular the advantage of being easy to use in a medical or veterinary context, for example in a hospital or clinic.

10 The subject of the present invention is an in vitro method of documenting a repertoire of (an) NKR immunoreceptor(s) comprising in particular the KIR p58.1, p58.2, p70.INH and p140.INH, and the NKG2A and NKG2B receptors, and/or of a repertoire of (an) NKR  
15 immunoreceptor counterpart(s), comprising in particular the KAR p50.1, p50.2, p70.ACT and p140.ACT receptors, and the NKG2C, NKG2D, NKG2E and NKG2F receptors, these immunoreceptors being designated hereinafter target receptor(s), characterized in that it comprises:  
20 i. the use of at least one pair of oligonucleotides, one being designated 3' oligonucleotide and the other 5' oligonucleotide, the 3' and 5' oligonucleotides of the same said pair both being capable, under hybridization conditions corresponding to incubation  
25 for 1 min in a buffer [20 mM Tris-HCl, pH 8.4; 50 mM KCl; 2.5 mM MgCl<sub>2</sub>] at a temperature of between 50°C and 65°C approximately, of hybridizing to the DNA or to the cDNA of a target NKR receptor, or NKR counterpart, but not hybridizing, under the same hybridization  
30 conditions, with the DNA or the cDNA of an NKR receptor counterpart, or respectively of an NKR receptor, functional counterpart of the said target receptor,  
ii. the bringing of DNA or cDNA populations of a biological sample of human or animal origin for which  
35 it is desired to document the repertoire of target immunoreceptor(s), into contact with an excess of at least one 3' and 5' oligonucleotide pair according to  
i. under conditions favourable to the hybridization of



this 3' and 5' oligonucleotide pair with the DNAs or cDNAs of the biological sample, and

- iii. the detection of the possible hybrids formed between these DNAs or cDNAs and the 3' and 5' oligonucleotide pair(s).

Functional counterpart of a receptor is understood to mean in the present application a receptor with a homologous structure, in particular at the extracytoplasmic level, but with a different function: for example, a functional counterpart of the NKR p58.1 receptor is the NKR p50.1 receptor counterpart, and conversely; likewise the NKR p58.2 receptor and the NKR p50.2 receptor counterpart are functional counterparts for one another.

- The present method therefore makes it possible in particular to distinguish an NKR receptor (or NKR counterpart) from a functional receptor counterpart of this receptor.

The 3' and 5' oligonucleotide pair(s) is (are) in particular capable of delimiting, on the DNA or the cDNA of a target receptor corresponding thereto, an oligonucleotide sequence (limits included) which is absent from the DNA or cDNA sequence of a receptor with which it (they) is (are) capable of not hybridizing under the hybridization conditions given under i) above.

- Advantageously, the said or at least one of the said 3' and 5' oligonucleotide pair(s) used is in addition capable, under the same hybridization conditions as those defined under i., of not hybridizing to the DNA or cDNA of a receptor, either NKR or NKR counterpart, other than the said target receptor.

- According to a particular arrangement of this advantageous manner, the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) capable, under the hybridization conditions defined under i. above, of hybridizing to the DNA or the cDNA of a p58.1 (or p50.1) receptor, and of not hybridizing to the DNA or

the cDNA of a p50.1 receptor (or respectively p58.1) is in addition capable of not hybridizing under the same hybridization conditions to the DNA or the cDNA of a p58.2 or p50.2 receptor.

5           According to a second particular arrangement of this advantageous manner, the said, or at least one of the said, 3' and 5' oligonucleotide pair(s) capable, under the hybridization conditions defined under i. above, of hybridizing to the DNA or the cDNA of a p58.2  
10 (or p50.2) receptor, and of not hybridizing to the DNA or the cDNA of a p50.2 (or respectively p58.2) receptor is in addition capable of not hybridizing under the same hybridization conditions to the DNA or the cDNA of a p58.1 or p50.1 receptor.

15           According to a third particular arrangement of this advantageous manner, the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) capable, under the hybridization conditions defined under i. above, of hybridizing to the DNA or the cDNA of a  
20 p70.INH (or p70.ACT) receptor, and of not hybridizing to the DNA or the cDNA of a p70.ACT (or respectively p70.INH) receptor is in addition capable of not hybridizing under the same hybridization conditions to the DNA or the cDNA of a p140.INH or p140.ACT receptor.

25           According to a fourth particular arrangement of this advantageous manner, the said, or at least one of the said, 3' and 5' oligonucleotide pair(s) capable, under the hybridization conditions defined under i. above, of hybridizing to the DNA or the cDNA of a  
30 p140.INH (or p140.ACT) receptor, and of not hybridizing to the DNA or the cDNA of a p140.ACT (or respectively p140.INH) receptor is in addition capable of not hybridizing under the same hybridization conditions to the DNA or the cDNA of a p70.INH or p70.ACT receptor.

35           According to an advantageous embodiment of the invention, the 5' oligonucleotide of a said 3' and 5' oligonucleotide pair used for an NKR target receptor (or NKR counterpart) is capable, under the hybridization conditions defined under i. above, of

hybridizing to the DNA or to the cDNA of an NKR receptor counterpart (or respectively NKR receptor), functional counterpart of the said NKR target receptor (or respectively NKR receptor counterpart). According to an advantageous arrangement of this embodiment, the 5' oligonucleotide sequence of a said 3' and 5' oligonucleotide pair used for an NKR target (or NKR counterpart) receptor comprises the 5' oligonucleotide sequence of another said 3' and 5' oligonucleotide pair having as target receptor an NKR receptor counterpart (or respectively NKR receptor), functional counterpart of the said NKR target receptor (or respectively NKR receptor counterpart).

According to another advantageous embodiment of the invention, the 3' oligonucleotide of a said 3' and 5' oligonucleotide pair, used for a KAR target receptor, is capable, under the same said hybridization conditions, of hybridizing to the DNA or cDNA of the said KAR target receptor at the level of a nucleotide stretch which comprises a sequence corresponding, according to the universal genetic code, and taking into account the degeneracy of the said code, to the amino acid sequence Lys Ile Pro Phe Thr Ile (K I P F T I) or Lys Leu Pro Phe Thr Ile (K L P F T I) (SEQ ID No. 26 or 27).

According to a particularly advantageous embodiment of the invention, the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) having as target receptor a KIR receptor is chosen from the group of 3' and 5' oligonucleotide pairs consisting of: a 5' oligonucleotide comprising the sequence SEQ ID No. 1, or a sequence which is derived therefrom, and at least one 3' oligonucleotide comprising the sequence SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom, a 5' oligonucleotide comprising the sequence SEQ ID No. 4, or a sequence which is derived therefrom, and at least one 3' oligonucleotide comprising the sequence

SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom,  
a 5' oligonucleotide comprising the sequence SEQ ID No. 9, or a sequence which is derived therefrom, and at  
5 least one 3' oligonucleotide comprising the sequence SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom,  
at least one 5' oligonucleotide comprising the sequence SEQ ID No. 10, No. 11, No. 12 or No. 13, or a sequence  
10 which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 14, or a sequence which is derived therefrom.

Sequence which is derived from a first sequence is understood to mean in the present application a  
15 sequence derived from the first in particular by inversion, deletion, addition or substitution of nucleotide(s), and exhibiting the hybridization properties which the nucleic acid corresponding to the first sequence exhibits under the conditions i. defined  
20 above.

According to one arrangement of this particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p58.1 receptor corresponds to a 5' oligonucleotide  
25 comprising SEQ ID No. 1, or a sequence which is derived therefrom, and an equal mixture of four 3' oligonucleotides, each of them comprising SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom.

30 According to another arrangement of this particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p58.2 receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 4, or a sequence which is derived  
35 therefrom, and an equal mixture of four 3' oligonucleotides, each of them comprising SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom.

According to yet another arrangement of this particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p70.INH receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 9, or a sequence which is derived therefrom, and an equal mixture of four 3' oligonucleotides, each of them comprising SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom.

According to yet another arrangement of this particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p140.INH receptor corresponds to an equal mixture of four 5' oligonucleotides, each of them comprising SEQ ID No. 10, No. 11, No. 12 or No. 13, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 14, or a sequence which is derived therefrom.

According to another particularly advantageous embodiment of the invention, the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) having as target receptor a KAR receptor is chosen from the group of 3' and 5' oligonucleotide pairs consisting of:

- a 5' oligonucleotide comprising the sequence SEQ ID No. 1, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom,
- a 5' oligonucleotide comprising the sequence SEQ ID No. 8, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom,
- a 5' oligonucleotide comprising the sequence SEQ ID No. 9, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom,
- a 5' oligonucleotide comprising the sequence SEQ ID No. 15, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom.

According to one arrangement of this other particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p50.1 receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 1, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 3, or a sequence which is derived therefrom.

According to another arrangement of this other particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p50.2 receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 8, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 3, or a sequence which is derived therefrom.

According to yet another arrangement of this other particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p70.ACT receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 9, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 3, or a sequence which is derived therefrom.

According to yet another arrangement of this other particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor a p140.ACT receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 15, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 3, or a sequence which is derived therefrom.

According to yet another particularly advantageous embodiment of the invention, the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) having as target receptor a NKG2 receptor is chosen from the group of 3' and 5' oligonucleotide pairs consisting of:

- a 5' oligonucleotide comprising the sequence SEQ ID No. 16, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 17, or a sequence which is derived therefrom,

- a 5' oligonucleotide comprising the sequence SEQ ID No. 18, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 17, or a sequence which is derived therefrom,

- a 5' oligonucleotide comprising the sequence SEQ ID No. 19, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 17, or a sequence which is derived therefrom,

- a 5' oligonucleotide comprising the sequence SEQ ID No. 20, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 21, or a sequence which is derived therefrom.

According to a first arrangement of this yet another particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor an NKG2A (inhibitor) receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 16, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 17, or a sequence which is derived therefrom.

According to a second arrangement of this yet another particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor an NKG2B (inhibitor) receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 18, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 17, or a sequence which is derived therefrom.

According to a third arrangement of this yet another particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor an NKG2C (activator) receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 19, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 17, or a sequence which is derived therefrom.

According to a fourth arrangement of this yet another particularly advantageous embodiment, the said 3' and 5' oligonucleotide pair having as target receptor an NKG2D (activator) receptor corresponds to a 5' oligonucleotide comprising SEQ ID No. 20, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising SEQ ID No. 21, or a sequence which is derived therefrom.

The said conditions which are favourable for the hybridization of the 3' and 5' oligonucleotide pair(s) brought into contact with the DNA or the cDNA of the biological sample advantageously correspond to an incubation for 1 min in a buffer [20 mM Tris-HCl, pH 8.4; 50 mM KCl; 2.5 mM MgCl<sub>2</sub>] at a temperature of between 50°C and 65°C approximately. Such conditions are in particular presented in the examples.

Advantageously, the two 3' or 5' oligonucleotides of the same said pair are each coupled to a marker, in particular coupled to a fluorescent or radioactive marker, such as <sup>32</sup>P, allowing the visualization of the hybrids which they may form with the said DNA or cDNA populations of the said biological sample.

In an equally advantageous manner, the said 3' and 5' oligonucleotide pair(s) serve(s) as 3' and 5' primers, respectively, for extension by DNA polymerase, such as a Taq polymerase. Conditions which are favourable for such an extension comprise, apart from the addition of DNA polymerase, the addition of the 4 dNTPs (deoxyribonucleoside triphosphates) in the presence of a Tris-HCl-type buffer.

The said hybrids which may be formed are then, prior to their detection, amplified by at least one PCR (amplification by the polymerase chain reaction; cf. patents EP 201,184 and EP 200,362) or RT-PCR in the case of cDNA retrotranscribed from mRNA. Where appropriate, the said hybrids which may be formed are amplified by nested PCR. Examples of conditions which



are favourable for the PCR amplification are given in the examples.

According to another advantageous embodiment of the invention, the said detection of the hybrids which  
5 may be formed comprises, in addition, the resolution, on a polyacrylamide gel, of the reaction mixture derived from the bringing into contact, as well as the visualization of the presence or of the absence of electrophoretic bands containing the said hybrids which  
10 may be formed.

According to another embodiment of the invention, the documented immunoreceptor repertoire is quantified with reference to the quantities of  $\beta$ -actin measured in the same biological sample, or with  
15 reference to the quantities of a specific molecule of a cellular type which are present in the said biological sample, such as in particular the CD56 molecules for the NK cells.

The method according to the invention may be  
20 applied to the documentation of a genotypic repertoire of NKR immunoreceptors and/or of NKR immunoreceptor counterparts: step ii. of the bringing into contact defined above is then carried out with the genomic DNA populations of the biological sample.

The method according to the invention may also  
25 be applied to the documentation of an expression repertoire of NKR immunoreceptors and/or of NKR immunoreceptor counterparts: step ii. of the bringing into contact defined above is then carried out with the  
30 cDNA populations retrotranscribed from the mRNA populations of the biological sample.

Biological samples of human or animal origin which are particularly appropriate for carrying out the method according to the invention comprise peripheral  
35 blood, bone marrow, lymphocytes, NK and/or T cells, transgenic cells expressing immunoreceptors and a fraction isolated from these samples.

The method according to the invention may be applied in particular to the screening of a library of organs, tissues or cells.

It thus allows better prediction:

- 5       - of the acceptance or rejection, by a human or an animal, of cells, of a tissue or of an organ which is (are) genetically different,
- of the safety or pathogenicity (GVH effect), for a human or an animal, of a graft or transplant, in
- 10       particular of cells, tissue or organ which is (are) genetically different,
- of a potential effect of the GVL type which cells, a tissue or an organ which is (are) genetically different could exert on a human or an animal.

15       The method according to the invention also allows the monitoring of the possible appearance of such reactions after allo- or xeno-genic grafting or transplantation.

          The method according to the invention can also

20       be applied to the determination of the state of activation of NK and/or T cells at a given instant in an animal or a human. It allows, in this case, the prediction or monitoring of the state of resistance of an animal or a human towards a viral infection, such as

25       an HIV infection, or a parasitic infection, such as malaria, or a bacterial infection, towards an autoimmune disease, such as rheumatoid arthritis, or alternatively towards the development of malignant cells such as leukaemia cells. The predictive use of

30       the method according to the invention is of particular importance in the context of epidemics.

          The method according to the invention can also be advantageously applied to the screening of medicaments which are active on infectious diseases, on

35       autoimmune diseases and on tumour diseases.

          The subject of the present invention is also a kit for carrying out the said method comprising, in a container, at least one said oligonucleotide pair, the reagents for carrying out the said method(s) such as a

buffer, a marker (optionally coupled to the oligonucleotides of the said pair), as well as instructions for use.

Other characteristics and advantages of the present invention will further emerge from the following exemplary embodiments which are given as a guide and without limitation.

The said examples refer to Figures 1 and 2:

Figure 1 represents the products derived from a PCR amplification (amplification by the polymerase chain reaction after enzymatic reverse transcription, RT, with the aid of oligonucleotide pairs according to the invention serving as primers), of the sequences encoding p50.2 (Fig. 1A) and p58.2 (Fig. 1B) in human NK cells;

Figure 2 represents the products derived from a PCR amplification of the sequence encoding p50.2 from the genomic DNA of p50.2<sup>+</sup> transgenic mice.

Example 1: Documentation of the NKR/NKR counterpart repertoire expressed by a population of human NK cells (RT-PCR).

#### 1. Preparation of the RNAs

RNA preparations were made from cloned human NK cells phenotyped p50.2<sup>+</sup> and/or p58.2<sup>+</sup>. Immunological technique does not make it possible to accurately document such a repertoire: the antibody GL183 (Immunotech) recognizes both the inhibitory NKR receptor p58.2 and its activatory counterpart p50.2. Cloned human NK cells phenotyped p50.2<sup>+</sup> and p58.2<sup>+</sup> with the aid of the antibody GL183 serve as negative controls.

The RNA preparations are made as follows.

#### Extraction

100 µl of Trizol (Gibco BRL category No. 15596-026) were added to 10<sup>6</sup> cells. The medium is mixed by pipetting several times, without using a vortex mixer. The solution is left for 5 minutes at room temperature and then 20 µl of chloroform, free of isoamyl alcohol, are added. The medium is again mixed without using a

vortex mixer and the solution is allowed to stand for 5 minutes at room temperature. It is then centrifuged at 4°C for 15 minutes so as to properly separate the bottom organic phase, which contains the DNA, from the top aqueous phase which contains the RNA. The aqueous phase is recovered without disturbing the interface between the aqueous phase and the organic phase.

#### Precipitation

50 µl of isopropanol are added to the aqueous phase and the RNA is allowed to precipitate for 15 minutes at room temperature. The medium is then centrifuged for 10 minutes at 4°C. The supernatant is removed, and the pellet is washed with 100 µl of 70% ethanol. After centrifuging for 5 minutes at 4°C (7500 g), the medium is allowed to dry in the open air (without drying under vacuum). The RNA pellet is resuspended in 20 ml of H<sub>2</sub>O.

#### 2. Preparation of the oligonucleotide pairs

Table 1 below presents the oligonucleotide pairs used. Reported here are the results relating to the use of the oligonucleotide pairs C (SEQ ID No. 4 as 5' oligonucleotide and an equal mixture of SEQ ID No. 5, No. 2, No. 6 and No. 7 as 3' oligonucleotide) and D (SEQ ID No. 8 as 5' oligonucleotide and SEQ ID No. 3 as 3' oligonucleotide) which are presented in Table 1. The cDNA sequences, on the basis of which these oligonucleotide pairs were developed, are presented in Table 2 below (name of the cDNA clones and Genbank accession number). For each oligonucleotide pair, the allelic variants and the excision-splicing variants (alternative splicing) known for the same receptor were thus taken into account.

Each oligonucleotide pair is constructed, after alignment of the known cDNA sequences of the different variants of the same target receptor (e.g. KIR p58.2), so that this pair can determine, on all these variants, the limits of a consensus fragment, without being able, as a result, to do likewise on any variant of the receptor counterpart of the target receptor (e.g. KAR

p50.2). The sequence of each oligonucleotide of the same pair is then optimized so that the annealing temperature for each of them is similar (e.g.  $\Delta T \leq 5^{\circ}\text{C}$ ).

- 5 Each oligonucleotide indeed has an annealing temperature which is specific to it. This annealing temperature depends on the ratio

$$10 \quad R = \frac{G + C}{\text{total number of bases}} \times 100 \quad \text{and on the}$$

length of the oligonucleotide considered, according to the formula: annealing temperature of an  
15 oligonucleotide =

$$T_m = 69.3 + 0.41(R) - \frac{650}{\text{length in bp}} \quad (\text{in } ^{\circ}\text{C})$$

20

- However, in a reaction of the polymerase chain reaction type, the oligonucleotides of the same pair should both be able to anneal to the target receptor under common reaction conditions, this being so as to  
25 serve as primers for the amplification of the consensus fragment. If the oligonucleotides of the same pair have similar specific annealing temperatures (e.g.  $54^{\circ}\text{C}$  and  $56^{\circ}\text{C}$ ), they will be able to hybridize to the target receptor, without, as a result, hybridizing to the  
30 corresponding receptor counterpart, at a temperature of  $54^{\circ}\text{C}$  or  $55^{\circ}\text{C}$ .

- If the oligonucleotides of the same pair have, on the other hand, very different specific annealing temperatures (e.g.  $49^{\circ}\text{C}$  and  $56^{\circ}\text{C}$ ), the reaction for  
35 hybridizing to the target receptor is preferably carried out at the lower of the two temperatures (e.g.  $49^{\circ}\text{C}$  or  $50^{\circ}\text{C}$ ), which makes it possible to maintain the recognition of its nucleotide target by the oligonucleotide whose specific annealing temperature is

the lowest. In this situation, a decrease in specificity can however occur: it is possible to observe that some oligonucleotide pairs succeed, under such temperature conditions, in hybridizing to the target receptor counterpart-receptor. A way of counteracting this loss of specificity consists in increasing the length of the oligonucleotide whose specific annealing temperature is the lowest, without causing the oligonucleotide pair considered to lose its specificity.

3. Amplification by the polymerase chain reaction after enzymatic reverse transcription (RT-PCR)

5  $\mu$ g of total RNA are transcribed into cDNA by incubating with a reverse transcriptase (RT) with the aid of the First Strand DNA-Ready to go kit (Pharmacia). 10  $\mu$ l of cDNA out of the 33  $\mu$ l obtained are brought into contact with oligonucleotide pairs C and D which serve, in this case, as primers (cf. Table 1): 10  $\mu$ l of RT-derived product; 10X PCR buffer: 10  $\mu$ l;  $MgCl_2$  50 mM; dXTP 10 mM; 3' oligonucleotide at 10  $\mu$ M: 5  $\mu$ l; 5' oligonucleotide 10  $\mu$ M: 5  $\mu$ l; Taq polymerase: 0.5  $\mu$ l;  $H_2O$ : qs 100  $\mu$ l. The PCR amplification (DNA engine PTC 200, MJ Research, Massachusetts) is carried out according to the following steps:

- step No. 1 (initial denaturation): 5 min at 94°C,
- step No. 2: 35 cycles comprising
  - a) denaturation 1 min at 94°C
  - 30 b) annealing 1 min at 55°C for the oligonucleotide pair C and 50°C for the oligonucleotide pair D,
  - c) extension 1 min at 72°C,
- step No. 3: (final extension):  
35 1 min at 72°C.

The duration of extension 2c can be increased if the fragment to be amplified is of a large size (e.g. greater than 1000-1400 bp approximately).

The temperature in the annealing step 2b depends on the pair of oligonucleotides used as primers (cf. point 2. above). It corresponds to a consensus temperature between the annealing temperatures specific for each of the two oligonucleotides forming a pair (mean temperature or the lower of the two temperatures). This temperature is generally between 45°C and 70°C, preferably between 50°C and 65°C.

10 10 µl of the products derived from the amplification by RT-PCR are resolved by electrophoresis on a 2% agarose gel in parallel with molecular weight markers (M).

The results are illustrated in Figures 1A and 1B.

15 Figure 1 illustrates the PCR amplification after RT (enzymatic reverse transcription) of the sequences encoding p58.2 and p50.2 of human NK cells.

In Figure 1A is illustrated the result of the electrophoretic resolution of the products derived from the RT-PCR amplification after bringing the pair of primers D according to the invention (cf. Table 1) into contact with the cDNA populations of human NK cells phenotyped p50.2<sup>+</sup> and p58.2<sup>+</sup> (lane +) with the aid of the antibody GL183, or with the cDNA populations of human NK cells phenotyped p50.2<sup>-</sup> and p58.2<sup>-</sup> (lane -) with the aid of this same antibody GL183. The molecular weight markers are resolved in lane M.

30 In Figure 1B is illustrated the result of the electrophoretic resolution of the products derived from the RT-PCR amplification after bringing the pair of primers C according to the invention (cf. Table 1) into contact with the cDNA populations of human NK cells phenotyped p50.2<sup>+</sup> and p58.2<sup>+</sup> (lane +) with the aid of the antibody GL183, or with the cDNA populations of human NK cells phenotyped p50.2<sup>-</sup> and p58.2<sup>-</sup> (lane -) with the aid of this same antibody GL183. The molecular weight markers are resolved in lane M.

35 It can be observed that the pairs of oligonucleotides C and D according to the invention

- make it possible to recognize respectively a phenotype, respectively, p58.2' and p50.2', by recognizing a fragment of, respectively, 653 bp and 533 bp. The method according to the invention therefore makes it possible to discriminate between a p58.2' phenotype (KIR receptor, with inhibitory function) and a p50.2' phenotype (KAR receptor counterpart of p58.2, with activatory function), which up until now could not be carried out by sequencing.
- 10 Example 2: Documentation of the NKR/NKR counterpart (potential) genetic repertoire of a population of p50.2' transgenic mouse splenocytes (PCR).

1 - Preparation of the DNAs

- DNA preparations were carried out using p50.2' transgenic mouse splenocytes. Immunological technique does not make it possible to determine if such splenocytes are p50.2' (KAR receptor, activatory) or p58.2' (KIR receptor, inhibitory, or alternatively p50.2' and p58.2'). Non-transgenic mouse splenocytes (p50.2') serve as negative controls.

Extraction

- This step is carried out as described in Example 1. The DNAs being contained in the bottom organic phase, it is this phase which is recovered here after having removed the aqueous phase and a small amount of interface.

Precipitation

- 30 µl of 100% ethanol are added and the medium is allowed to stand for 5 minutes at room temperature. After centrifuging for 5 minutes at 4°C (2000 g), the supernatant is discarded and the pellet is washed with 100 µl of 0.1 M sodium citrate in 10% ethanol. The medium is left for 30 minutes at room temperature while mixing from time to time. It is centrifuged for 5 minutes at 4°C (2000 g). This washing is repeated a second time.

The DNA pellet obtained is resuspended in 200 µl of 70% ethanol. The medium is left for 15



minutes at room temperature while mixing from time to time and centrifuged for 5 minutes at 4°C (2000 g).

The pellet is left to dry briefly under vacuum (1 to 2 µg of DNA approximately are obtained) and is resuspended in 10 µl of 8 mM NaOH. If insoluble material is present, the medium is microcentrifuged for 10 minutes at room temperature. The supernatant is transferred into a new tube. The pH is neutralized by adding 1.25 µl of 0.1 M Hepes per 10 µl.

10        2 - Preparation of the oligonucleotide pairs

The oligonucleotide pairs are prepared as described in Example 1. Reported here are the results relating to the oligonucleotide pair D (SEQ ID No. 8 as 5' oligonucleotide and SEQ ID No. 3 as 3' oligonucleotide) according to the invention (cf. Table 1 below).

15        3 - Amplification by the polymerase chain reaction (PCR)

Amplification by the polymerase chain reaction is carried out as described in Example 1 by bringing the genomic DNA preparations obtained into contact with oligonucleotide pairs D which serve, in this case, as primers.

The products derived from the amplification are resolved on 2% agarose gel in parallel with molecular weight markers (M).

The results of electrophoretic resolution on 2% agarose gel of the PCR-derived products are illustrated by Figure 2.

30        Figure 2 illustrates the PCR amplification of the sequence encoding p50.2 from the genomic DNA of p50.2' transgenic mouse splenocytes: illustrated therein is the result of the electrophoretic resolution of the products derived from PCR amplification after bringing the pair of primers D according to the invention (cf. Table 1) into contact with the DNA populations of splenocytes of p50.2' transgenic mice (lanes +) or of p50.2' non-transgenic mice (lanes -). The molecular weight markers are resolved in lane M.

The D primers according to the invention make it possible to recognize a fragment of 533 bp present on the DNA of p50.2<sup>+</sup> murine splenocytes and absent from the DNA of p50.2<sup>-</sup> murine splenocytes.

- 5        Similar results were obtained with the oligonucleotide pairs A, B and E to L presented in Table 1 below and also made it possible to document the desired receptors (cf. "molecule" column of Table 1).

- 10       The NKR and/or NKR counterpart repertoires thus documented can be, in particular with the aid of conventional biostatic studies, correlated with given physiological or pathological situations linked to these repertoires, and with the control of the activation of the cells expressing them in general.

TABLE 1

Oligo pair	Molecule	Function	Tm	Name of oligo	Sequence of the oligo (5'-->3')	Oligo 5' sequence
A	p58.EB6 (p58.1)	Inhibitory	56°C	p58.1 FOR ITIM N-term BACK	AGTCGATGACGCAAGAC CAACTGTG(T/C) (A/G)TATGTCAC	Seq ID NO.1 Seq ID NO.5,2,6,7
B	p50.EB6 (p50.1)	Activatory	56°C	p58.1 FOR TM-ACT BACK	AGTCGATGACGCAAGAC GATGGTGAAGGGAATTT	Seq ID NO.1 Seq ID NO.3
C	p58.1B3 (p58.2)	Inhibitory	56°C	p58.2 FOR ITIM N-term BACK	GGTCCCATGATGCAAGAC CAACTGTG(T/C) (A/G)TATGTCAC	Seq ID NO.4 Seq ID NO.5,2,6,7.
D	p50.1B3 (p50.2)	Activatory	56°C	p58.2 FOR TM-ACT BACK	GGTCCCATGATGCAAGAC GATGGTGAAGGGAATTT	Seq ID NO.8 Seq ID NO.3

05529759.001B00

TABLE 1 (continued)

E	P70. INH	Inhibitory	58°C 54°C	P70. PRO ITIM N-term BACK	CCCGTGTGATCATGTGTC CAACTGTG(T/C) (A/G) TMTGTAC	Seq ID NO.9 Seq ID NO.5,2,6,7.
F	P70. ACT	Activatory	58°C 49°C	P70. FOR TM-ACT BACK	CCCGTGTGATCATGTGTC GATGTGTAAGGATTTT	Seq ID NO.9 Seq ID NO.3
G	p140. INH	Inhibitory	56°C 58°C	ITIM N-term. FOR Ext C-term BACK	GTGAC (A/G) TNC (A/G) CACAGTTG ACCTGACTGTGTGCTCG	Seq ID NO.10,11,12,13 Seq ID NO.14
H	p140. ACT	Activatory	58°C 49°C	p140. FOR TM-ACT BACK	ACCTACAGATTTATGTTCTGTT GATGTGTAAGGATTTT	Seq ID NO.15 Seq ID NO.13
I	NKG2A	Inhibitory	54°C 54°C	NKG2A FOR NKG2A/B/C. BACK	TCTACATTATATACAGAGGCAC ATCTATAGAAAGCAGACT	Seq ID NO.16 Seq ID NO.17

00529759.011803

TABLE 1 (continued)

J	NKG2B	Inhibitory	52°C 54°C	NKG2B.FOR NKG2B/B.C.BACK	ATTCCTCACGTCATTGT ATCTATAGAAAAGAGACT	Seq ID NO.18 Seq ID NO.17
K	NKG2C	Activatory	54°C 54°C	NKG2C.FOR NKG2A/B.C.BACK	AGTAACAAAGAGAACCTTC ATCTATAGAAAAGAGACT	Seq ID NO.19 Seq ID NO.17
L	NKG2D	Activatory	56°C 58°C	NKG2D.FOR NKG2D.BACK	ACCAAGAGAACGAGATTTA CACAGTCTTTGATGAGAT	Seq ID NO.20 Seq ID NO.21
M	CD56		51°C 54°C	5' hCD56 3' hCD56	ATCCAGTACACTGATGAC GTGATGATGGTGAGA	Seq ID NO.22 Seq ID NO.23
N	Actine		62°C 64°C	5' Actine 3' Actine	TACCACTGGCATCGTATGACT TCCTTCTGCATCTCTGTGGCAAT	Seq ID NO.24 Seq ID NO.25

TABLE 2

oligonucleotide pair	Name of the cDNA	Genbank accession number
A	cl-42	U24076
	NKAT-I	L41267
	cl-47.11	U24078
B	X98858	X98585
	X98892	X98892
	NKAT-7AA	L76670
	NKAT-9AA	L76672
C	cl-43	U24075
	NKAT-6AA	L76669
	NKAT-2BA	L76663
	cl-6	U24074
	NKAT-2	L41268
	KIR-023GB	U73395
	NKAT-2AB	L76662
D	NKAT-3DA	L76664
	cl-49	U24079
	NKAT-5	L41347
	X89893	X89893
	cl-39	U24077
	NKAT-8	L76671
	NKAT-5DA	L76667

TABLE 2 (continued)

E	X94262	X94262
	NKAT-3	L41269
	NKBI-1	U31416
	NKBI-2	U33328
	KIR-103AS	U71199
	KIR-103AST	U73394
	c1-1.1	X94373
	c1-11	U30274
	c1-2	U30273
F	NKAT-10	L76661
	KIR-123FM	U73396
G	NKAT-4	L41270
	X94374	X94374
	X93595	X93595
	X93596	X93596
	NKAT-4BA	L76666
	NKAT-4AA	L76665
	c1-5	U30272
I	NKG2A	X54867
J	NKG2B	X54868
K	NKG2C	X54869
L	NKG2D	X54870

CLAIMS

1. *In vitro* method of documenting a repertoire of (an) NKR immunoreceptor(s) comprising in particular the
- 5 KIR p58.1, p58.2, p70.INH and p140.INH, and the NKG2A and NKG2B receptors, and/or of a repertoire of (an) NKR immunoreceptor counterpart(s), comprising in particular the KAR p50.1, p50.2, p70.ACT and p140.ACT receptors, and the NKG2C, NKG2D, NKG2E and NKG2F receptors, these
- 10 immunoreceptors being designated hereinafter target receptor(s), characterized in that it comprises:
- i. the use of at least one pair of oligonucleotides, one being designated 3' oligonucleotide and the other 5' oligonucleotide, the 3' and 5' oligonucleotides of
- 15 the same said pair both being capable, under hybridization conditions corresponding to incubation for 1 min in a buffer [20 mM Tris-HCl, pH 8.4; 50 mM KCl; 2.5 mM MgCl<sub>2</sub>] at a temperature of between 50°C and 65°C approximately, of hybridizing to the DNA or to the
- 20 cDNA of a target NKR receptor, or NKR counterpart, but not hybridizing, under the same hybridization conditions, with the DNA or the cDNA of an NKR receptor counterpart, or respectively of an NKR receptor, functional counterpart of the said target receptor,
- 25 ii. the bringing of DNA or cDNA populations of a biological sample of human or animal origin for which it is desired to document the repertoire of (a) target immunoreceptor(s), into contact with an excess of at least one 3' and 5' oligonucleotide pair according to
- 30 i. under conditions favourable to the hybridization of this 3' and 5' oligonucleotide pair with the DNAs or cDNAs of the biological sample, and
- iii. the detection of the possible hybrids formed between these DNAs or cDNAs and the 3' and 5' oligonucleotide pair(s).
- 35

2. Method according to Claim 1, characterized in that the said or at least one of the said 3' and 5' oligonucleotide pair(s) used is in addition capable,



under the same hybridization conditions as those defined under i., of not hybridizing to the DNA or cDNA of a receptor, either NKR or NKR counterpart, other than the said target receptor.

5 3. Method according to any one of the preceding claims, characterized in that the 5' oligonucleotide of a said 3' and 5' oligonucleotide pair used for an NKR target receptor (or NKR counterpart) is capable, under the same said hybridization conditions, of hybridizing  
10 to the DNA or to the cDNA of an NKR receptor counterpart (or respectively NKR receptor), functional counterpart of the said NKR target receptor (or respectively NKR receptor counterpart).

4. Method according to any one of the preceding  
15 claims, characterized in that the 3' oligonucleotide of a said 3' and 5' oligonucleotide pair, used for a KAR target receptor, is capable, under the same said hybridization conditions, of hybridizing to the DNA or cDNA of the said KAR target receptor at the level of a  
20 nucleotide stretch which comprises a sequence corresponding, according to the universal genetic code, and taking into account the degeneracy of the said code, to the amino acid sequence Lys Ile Pro Phe Thr  
Ile (K I P F T I) or Lys Leu Pro Phe Thr Ile (K L P F T  
25 I) (SEQ ID No. 26 or 27).

5. Method according to any one of the preceding claims, characterized in that the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) having as target receptor a KIR receptor is chosen from the  
30 group of 3' and 5' oligonucleotide pairs consisting of:  
a 5' oligonucleotide comprising the sequence SEQ ID No. 1, or a sequence which is derived therefrom, and at least one 3' oligonucleotide comprising the sequence  
SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence  
35 which is derived therefrom,  
a 5' oligonucleotide comprising the sequence SEQ ID No. 4, or a sequence which is derived therefrom, and at least one 3' oligonucleotide comprising the sequence

SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom,

a 5' oligonucleotide comprising the sequence SEQ ID No. 9, or a sequence which is derived therefrom, and at

5 least one 3' oligonucleotide comprising the sequence SEQ ID No. 5, No. 2, No. 6 or No. 7, or a sequence which is derived therefrom,

at least one 5' oligonucleotide comprising the sequence SEQ ID No. 10, No. 11, No. 12 or No. 13, or a sequence

10 which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 14, or a sequence which is derived therefrom.

6. Method according to any one of the preceding claims, characterized in that the said (or at least one  
15 of the said) 3' and 5' oligonucleotide pair(s) having as target receptor a KAR receptor is chosen from the group of 3' and 5' oligonucleotide pairs consisting of:

- a 5' oligonucleotide comprising the sequence SEQ ID No. 1, or a sequence which is derived therefrom, and a

20 3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom,

- a 5' oligonucleotide comprising the sequence SEQ ID No. 8, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID

25 No. 3, or a sequence which is derived therefrom,

- a 5' oligonucleotide comprising the sequence SEQ ID No. 9, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID

No. 3, or a sequence which is derived therefrom,

30 - a 5' oligonucleotide comprising the sequence SEQ ID No. 15, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 3, or a sequence which is derived therefrom.

7. Method according to any one of the preceding  
35 claims, characterized in that the said (or at least one of the said) 3' and 5' oligonucleotide pair(s) having

as target receptor a NKG2 receptor is chosen from the group of 3' and 5' oligonucleotide pairs consisting of:

- a 5' oligonucleotide comprising the sequence SEQ ID No. 16, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 17, or a sequence which is derived therefrom,
- 5 a 5' oligonucleotide comprising the sequence SEQ ID No. 18, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 17, or a sequence which is derived therefrom,
- 10 a 5' oligonucleotide comprising the sequence SEQ ID No. 19, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 17, or a sequence which is derived therefrom,
- 15 a 5' oligonucleotide comprising the sequence SEQ ID No. 20, or a sequence which is derived therefrom, and a 3' oligonucleotide comprising the sequence SEQ ID No. 21, or a sequence which is derived therefrom.
8. Method according to any one of the preceding claims, characterized in that the two 3' or 5' oligonucleotides of the same said pair are each coupled
- 20 to a marker, in particular coupled to a fluorescent or radioactive marker, such as <sup>32</sup>P, allowing the visualization of the hybrids which they may form with the said DNA or cDNA populations of the said biological sample.
- 25 9. Method according to any one of the preceding claims, characterized in that the said 3' and 5' oligonucleotide pair(s) serve(s) as 3' and 5' primers, respectively, for extension by DNA polymerase.
- 30 10. Method according to any one of the preceding claims, characterized in that the said hybrids which may be formed are amplified by at least one PCR prior to their detection.
11. Method according to any one of the preceding claims, characterized in that the said hybrids which
- 35 may be formed are amplified by nested PCR.
12. Method according to any one of the preceding claims, characterized in that the said detection of the hybrids which may be formed comprises, in addition, the

resolution, on a polyacrylamide gel, of the reaction mixture derived from the bringing into contact, as well as the visualization of the presence or of the absence of electrophoretic bands containing the said hybrids which may be formed.

13. Method according to any one of the preceding claims, characterized in that it is applied to the documentation of a genotypic repertoire of NKR immunoreceptors and/or of NKR immunoreceptor counterparts.

14. Method according to any one of the preceding claims, characterized in that it is applied to the documentation of an expression repertoire of NKR immunoreceptors and/or of NKR immunoreceptor counterparts.

15. Method according to any one of the preceding claims, characterized in that the said biological sample of human or animal origin is peripheral blood, bone marrow, lymphocytes, NK and/or T cells, transgenic cells expressing immunoreceptors and a fraction isolated from these samples.

16. Method according to any one of the preceding claims, characterized in that it is applied to the screening of a library of organs, tissues or cells.

17. Method according to any one of the preceding claims, characterized in that it is applied to the prediction or to the monitoring of the acceptance or rejection, by a human or an animal, of cells, tissue or organ which is (are) genetically different.

18. Method according to any one of the preceding claims, characterized in that it is applied to the prediction or to the monitoring of the safety or of the pathogenicity (GVH), for a human or an animal, of a graft or transplant, of cells, tissue or organ which is (are) genetically different.

19. Method according to any one of the preceding claims, characterized in that it is applied to the prediction or to the monitoring, for a human or an

animal, of a GVL-type effect on the part of cells, tissue or organ which is (are) genetically different.

20. Method according to any one of the preceding claims, characterized in that it is applied to the  
5 determination of the state of activation of NK and/or T cells at a given instant in an animal or a human.

21. Method according to any one of the preceding claims, characterized in that it is applied to the prediction or to the monitoring of the state of  
10 resistance of an animal or a human towards a viral infection, such as an HIV infection, or a parasitic infection, such as malaria, or a bacterial infection, towards an autoimmune disease, such as rheumatoid arthritis, or alternatively towards the development of  
15 malignant cells such as leukaemia cells.

22. Method according to any one of the preceding claims, characterized in that it is applied to the screening of medicaments which are active on infectious diseases, on autoimmune diseases and on tumour  
20 diseases.

23. Kit for carrying out the method according to any one of Claims 1 to 22, characterized in that it comprises, in a container, at least one said 3' and 5' oligonucleotide pair, the reagents for carrying out the  
25 said method(s) such as a buffer, a marker (optionally coupled to the oligonucleotides of the said pair), as well as instructions for use.

SEQUENCE LISTING

(1) GENERAL INFORMATION

5

(i) APPLICANT:

- (A) NAME: I. N. S. E. R. M
- (B) STREET: 101 rue de Tolbiac
- (C) CITY: PARIS
- (E) COUNTRY: FRANCE
- (F) POSTAL CODE: 75654

10

(ii) TITLE OF INVENTION: Method of documenting NKR immunoreceptors and NKR immunoreceptor counterparts

15

(iii) NUMBER OF SEQUENCES: 27

(iv) COMPUTER READABLE FORM

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

20

25 (2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleotide
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: Other nucleic acid

35

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: p58.1 FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

REPLACEMENT PAGE (RULE 26)

AGTCGCATGA CCCAAGAC

18

(3) INFORMATION FOR SEQ ID NO: 2:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

10

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

15

(C) INDIVIDUAL/ISOLATE: ITIM N-term BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CAACTGTGTG TATGTCAC

18

20

(4) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

25

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

30

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: TM-ACT BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

35

GATGGTGAAA GGGATTTT

18

(5) INFORMATION FOR SEQ ID NO: 4:

REPLACEMENT PAGE (RULE 26)

(i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 18 base pairs  
    (B) TYPE: nucleotide  
5      (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
(vi) ORIGINAL SOURCE:  
10      (C) INDIVIDUAL/ISOLATE: p58.2 FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:  
  
GGTCCCATGA TGCAAGAC 18

15      (6) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 18 base pairs  
20      (B) TYPE: nucleotide  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid  
25      (vi) ORIGINAL SOURCE:  
        (C) INDIVIDUAL/ISOLATE: ITIM N-term BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:  
30      CAACTGTGTA TATGTCAC 18

(7) INFORMATION FOR SEQ ID NO: 6:

35      (i) SEQUENCE CHARACTERISTICS:  
        (A) LENGTH: 18 base pairs  
        (B) TYPE: nucleotide  
        (C) STRANDEDNESS: single

REPLACEMENT PAGE (RULE 26)



(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

5 (C) INDIVIDUAL/ISOLATE: ITIM N-term BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CAACTGTGCA TATGTCAC 18

10

(8) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

15 (B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

20

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: ITIM N-term BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

25

CAACTGTGCG TATGTCAC 18

(9) INFORMATION FOR SEQ ID NO: 8:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

35 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: p58.2 FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

5 GGTCCCATGA TGCAAGAC 18

(10) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 18 base pairs  
(B) TYPE: nucleotide  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: p70.FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

20 CCCGTGGTGA TCATGGTC 18

(11) INFORMATION FOR SEQ ID NO: 10:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs  
(B) TYPE: nucleotide  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: ITIM N-term. FOR

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GTGACATACA CACAGTTG 18

(12) INFORMATION FOR SEQ ID NO: 11:

5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
(B) TYPE: nucleotide  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: Other nucleic acid  
10 (vi) ORIGINAL SOURCE:  
(C) INDIVIDUAL/ISOLATE: ITIM N-term. FOR  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:  
15 GTGACATACG CACAGTTG 18

(13) INFORMATION FOR SEQ ID NO: 12:

20 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
(B) TYPE: nucleotide  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
25 (ii) MOLECULE TYPE: Other nucleic acid  
(vi) ORIGINAL SOURCE:  
(C) INDIVIDUAL/ISOLATE: ITIM N-term. FOR  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:  
30 GTGACGTACA CACAGTTG 18

(14) INFORMATION FOR SEQ ID NO: 13:

35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
(B) TYPE: nucleotide  
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

5 (C) INDIVIDUAL/ISOLATE: ITIM N-term. FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GTGACGTACG CACAGTTG 18

10

(15) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

15 (B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

20 (vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: Ext C-term BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

25 ACCTGACTGT CGTGCTCG 18

(16) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 24 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: p140.FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

ACCTACAGAT GTTATGGTTC TGTT

24

5 (17) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleotide

10 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: NKG2A.FOR

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

TCTACATTAA TACAGAGGCA C

21

20 (18) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleotide

25 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

30 (C) INDIVIDUAL/ISOLATE: NKG2A/B/C. BACK

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

ATCTATAGAA AGCAGACT

18

35

(19) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

REPLACEMENT PAGE (RULE 26)

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleotide
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5

- (ii) MOLECULE TYPE: Other nucleic acid
- (vi) ORIGINAL SOURCE:
  - (C) INDIVIDUAL/ISOLATE: NKG2 B FOR

10

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

ATTCCTCAC GTCATTGT 18

- (20) INFORMATION FOR SEQ ID NO: 19:

15

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleotide
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

20

- (ii) MOLECULE TYPE: Other nucleic acid
- (vi) ORIGINAL SOURCE:
  - (C) INDIVIDUAL/ISOLATE: NKG2C. FOR

25

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

AGTAAACAAA GAGGAACCTT C 21

30

- (21) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 21 base pairs
  - (B) TYPE: nucleotide
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

35

- (ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:  
(C) INDIVIDUAL/ISOLATE: NKG2D. FOR

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

5

AGCAAAGAGG ACCAGGATTT A 21

(22) INFORMATION FOR SEQ ID NO: 21:

10 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: NKG2D. BACK

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

CACAGTCCTT TGCATGCAGA T 21

(23) INFORMATION FOR SEQ ID NO: 22:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs

(B) TYPE: nucleotide

(C) STRANDEDNESS: single

30

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: 5' hCD56

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

ATCCACTACA CTGATGAC 18

(24) INFORMATION FOR SEQ ID NO: 23:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 18 base pairs  
(B) TYPE: nucleotide  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: 3' hCD56

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

15

GTCGATGGAT GGTGAAGA

18

(25) INFORMATION FOR SEQ ID NO: 24:

- 20 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 base pairs  
(B) TYPE: nucleotide  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25

(ii) MOLECULE TYPE: Other nucleic acid

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: 5' Actin

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

TACCACTGGC ATCGTGATGG ACT

23

(26) INFORMATION FOR SEQ ID NO: 25:

35

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 23 base pairs  
(B) TYPE: nucleotide



(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other nucleic acid

5 (vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE: 3' Actin

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

10 TCCTTCTGCA TCCTGTCGGC AAT 23

(27) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL/ISOLATE:

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26

Lys Ile Pro Phe Thr Ile

1 5

30

(28) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

35 (B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(vi) ORIGINAL SOURCE:

5 (C) INDIVIDUAL/ISOLATE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27

Lys Leu Pro Phe Thr Ile

10 1 5

## ABSTRACT OF THE INVENTION

The invention relates to an *in vitro* method for documenting a repertoire in NKR immunoreceptors and/or NKR counterparts, consisting of (i) using at least a pair of oligonucleotides 3' and 5' capable of hybridizing with a target NKR receptor, or NKR counterpart, and not capable of being hybridized with a functional counterpart of said target receptor; (ii) contacting said pair of oligonucleotides 3' and 5' with the DNA or DNA of a sample under study; and (iii) detecting the ultimately formed hybrids. The invention also concerns the biological applications of said method, in particular for screening banks of organs, tissues and cells for transplant, and kits for its implementation.

FIGURE 1B



FIGURE 1A




FIGURE 1

FIGURE 2



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**Declaration and Power of Attorney for Patent Application**  
**Déclaration et Pouvoirs pour Demande de Brevet****French Language Declaration**

En tant que l'inventeur nommé ci-après, je déclare par le présent acte que

As a below named inventor, I hereby declare that

Mon domicile, mon adresse postale et ma nationalité sont ceux figurant ci-dessous à côté de mon nom

My residence, post office address and citizenship are as stated next to my name.

Je crois être le premier inventeur original et unique (si un seul nom est mentionné ci-dessous), ou l'un des premiers co-inventeurs originaux (si plusieurs noms sont mentionnés ci-dessous) de l'objet revendiqué, pour lequel une demande de brevet a été déposée concernant l'invention intitulée

I believe I am the original, first and sole inventor (if only one name is listed below) or an original (first and joint) inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**VIVIER Eric****20bis, Chemin du Boudard  
13260 CASSIS FRANCE****VELY Frédéric****Résidence du Vallat - La Farendole-  
13260 CASSIS FRANCE**

Cette déclaration est du type suivant

This declaration is of the following type

original	[ ]	original
modèle	[ ]	design
phase nationale du PCT	[ X ]	national stage of PCT
divisionnaire	[ ]	divisional
continuation	[ ]	continuation
continuation en parties (C-I-P)	[ ]	continuation-in-part (C-I-P)

the specification of which is attached hereto unless the following box is checked:

et dont la description est fournie ci-joint à moins que la case suivante n'ait été cochée

[ X ] a été déposée  
le 20/10/98  
sous le numéro de demande des États-Unis ou le  
numéro de demande internationale PCT/R98/02244  
et modifiée le  
(le cas échéant)

[ ] was filed on  
as United States Application Number or PCT  
International Application Number  
and was amended on  
(if applicable).

Je déclare par le présent acte avoir passé en revue et compris le contenu de la description ci-dessus, revendications comprises, telles que modifiées par toute modification dont il aura été fait référence ci-dessus

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above

Je reconnais devoir divulguer toute information pertinente à la brevetabilité, comme défini dans le Titre 37, § 1.56 du Code fédéral des réglementations.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

[ ] Conformément aux termes de cette obligation, les informations exigées sont jointes 37 CFR 1.98 aux présentes

[ ] In compliance with this duty there is attached an information disclosure statement 37 CFR 1.98.

[Page 1 of 3]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

**French Language Declaration**

Je revendique par le présent acte avoir la priorité énoncée, en vertu du Titre 35, § 119(a)-(d) ou § 365(b) du Code des États-Unis, sur toute demande étrangère de brevet ou certificat d'inventeur ou, en vertu du Titre 35, § 365(a) du même Code, sur toute demande internationale PCT désignant un pays autre que les États-Unis et figurant ci-dessous et, en cochant la case, j'ai aussi indiqué ci-dessous toute demande étrangère de brevet, tout certificat d'inventeur ou toute demande internationale PCT ayant une date de dépôt précédant celle de la demande à propos de laquelle une priorité est revendiquée.

Prior foreign application(s)

Demande(s) de brevet antérieure(s)

97 13115	FRANCE
(Number)	(Country)
(Numero)	(Pays)

(Number)	(Country)
(Numero)	(Pays)

(Number)	(Country)
(Numero)	(Pays)

Je revendique par le présent acte tout bénéfice, en vertu du Titre 35, § 119(e) du Code des États-Unis, de toute demande de brevet provisoire effectuée aux États-Unis et figurant ci-dessous.

(Application No.)
(N° de demande)

(Application No.)
(N° de demande)

Je revendique par le présent acte tout bénéfice, en vertu du Titre 35, § 120 du Code des États-Unis, de toute demande de brevet effectuée aux États-Unis, ou en vertu du Titre 35, § 365(c) du même Code, de toute demande internationale PCT désignant les États-Unis et figurant ci-dessous et, dans la mesure où l'objet de chacune des revendications de cette demande de brevet n'est pas divulgué dans la demande antérieure américaine ou internationale PCT, en vertu des dispositions du premier paragraphe du Titre 35, § 112 du Code des États-Unis, je reconnais devoir divulguer toute information pertinente à la brevetabilité, comme défini dans le Titre 37, § 1.56 du Code fédéral des réglementations, dont j'ai pu disposer entre la date de dépôt de la demande antérieure et la date de dépôt de la demande nationale ou internationale PCT de la présente demande.

(Application No.)	(Filing Date)
(N° de demande)	(Date de dépôt)

(Application No.)	(Filing Date)
(N° de demande)	(Date de dépôt)

Je déclare par le présent acte que toute déclaration ci-incluse est, à ma connaissance, véridique et que toute déclaration fournie à partir de renseignements ou de suppositions est tenue pour véridique et de plus, que toutes ces déclarations ont été fournies en sachant que toute fausse déclaration volontaire ou son équivalent est passible d'une amende ou d'une incarcération, ou des deux, en vertu de la Section 1001 du Titre 18 du Code des États-Unis, et que de telles déclarations volontairement fausses risquent de compromettre la validité de la demande de brevet ou du brevet délivré à partir de celle-ci.

I hereby claim foreign priority under Title 35, United States Code, § 119(a)-(d) or § 365 (b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below, and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Priority Claimed

Date de priorité revendiquée

(Day/Month/Year Filed)	[ ]
(Jour/Mois/Année de dépôt)	

(Day/Month/Year Filed)	[ ]
(Jour/Mois/Année de dépôt)	

(Day/Month/Year Filed)	[ ]
(Jour/Mois/Année de dépôt)	

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Filing Date)
(Date de dépôt)

(Filing Date)
(Date de dépôt)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

(Status) (patented, pending, abandoned)
(Statut) (breveté, en cours d'examen, abandonné)

(Status) (patented, pending, abandoned)
(Statut) (breveté, en cours d'examen, abandonné)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## French Language Declaration



**POLYVOIRS** En tant que l'inventeur cité, je déclare par la présente l'(les) avocat(s) et/ou agent(s) suivant(s) pour qu'ils poursuive(nt) la procédure de cette demande de brevet et traitent(nt) toute affaire s'y rapportant avec l'Office des brevets et des marques. (mentionner le nom et le numéro d'enregistrement)

**POWER OF ATTORNEY.** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: (list name and registration number)

Dana M. Raymond, Reg. No. 18,540; Frederick C. Carver, Reg. No. 17,021; Francis J. Hone, Reg. No. 18,662; Joseph D. Garon, Reg. No. 20,420; Arthur S. Tenser, Reg. No. 18,839; Ronald B. Hildreth, Reg. No. 19,496; Thomas R. Nesbitt, Jr., Reg. No. 22,075; Robert Neuner, Reg. No. 24,316; Richard G. Berkley, Reg. No. 25,465; Richard S. Clark, Reg. No. 26,154; Bradley B. Geel, Reg. No. 27,551; James J. Maune, Reg. No. 26,946; John D. Murnane, Reg. No. 29,636; Henry Tang, Reg. No. 29,705; Robert C. Schenfeld, Reg. No. 31,300; John A. Fogarty, Jr., Reg. No. 22,540; Louis B. Sorel, Reg. No. 32,435; Rochelle K. Seide, Reg. No. 32,300; Gary M. Butler, Reg. No. 33,841; Maria E. Detergore, Reg. No. 32,889; and Lisa B. Kole, Reg. No. 35,225.

Send Correspondence to  
Addresser toute correspondance à  
Baker Botts L.L.P.  
30 Rockefeller Plaza  
New York, New York 10112-4498  
Customer Number 21003

Direct Telephone Calls to  
Addresser tout appel téléphonique à  
(nom et numéro de téléphone)  
Baker Botts L.L.P.  
212-406-2500


Full name of sole or first inventor Nom complet de l'inventeur ou premier inventeur <b>ERIC VMIER</b>	Full name of second joint inventor, if any Nom complet de second co-inventeur, le cas échéant <b>Frédéric VELY</b>
Inventor's signature Signature de l'inventeur  Date <b>March 27, 2000</b>	Second inventor's signature Signature du second co-inventeur  Date <b>March 27, 2000</b>
Residence Domicile <b>20bis, Chemin du Boudard 13260 CASSIS FRANCE</b> <b>FRX</b>	Residence Domicile <b>Residence du Vallat La Farendole 13260 CASSIS FRANCE</b> <b>FRX</b>
Citizenship Nationalité <b>Française (French)</b>	Citizenship Nationalité <b>Française (French)</b>
Post Office Address Adresse postale <b>20bis, Chemin du Boudard 13260 CASSIS FRANCE</b>	Post Office Address Adresse postale <b>Residence du Vallat La Farendole 13260 CASSIS FRANCE</b>

(Fournir les mêmes renseignements et la signature de tout co-inventeur supplémentaire.)

(Supply similar information and signature for third and subsequent joint inventors.)



United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☒ Scanned copy is best available.

*Declaration is power of Attorney*